Enliven Therapeutics (ELVN) executive compensation, 2026 proxy

Richard Fair, M.B.A., President and Chief Executive Officer, was paid $11.9M in 2025.

Filed
April 27, 2026
Annual meeting
June 9, 2026
Pay year
2025
Named executives
4
CEO total pay
$11.9M2025
CEO Base Salary
$660,000Current annual base salary
CEO Target Bonus
55%Percentage of annual base salary
Bonus Payout
90%Achieved payout under 2025 Bonus Plan
CMO Base Salary
$545,000Approved in January 2026
CFO Base Salary
$530,000Approved in January 2026
Consulting Fee
$41,667Monthly payment for former CEO

How M.B.A. was paid

$11.9M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.

Salary0%Option awards100%All other compensation0%

Named executive officers

ExecutiveTotal
Richard Fair, M.B.A.President and Chief Executive Officer$11,918,926
Sam Kintz, M.B.A.Former President and Chief Executive Officer$8,908,647
Helen Collins, M.D.Chief Medical Officer$3,501,699
Ben HohlChief Financial Officer$3,443,173

What changed and why

  • $660KRichard Fair commenced employment as President and Chief Executive Officer on December 11, 2025 with a base salary of $660,000.
  • Sam Kintz transitioned from President and Chief Executive Officer to Head of Pipeline effective December 11, 2025.
  • 90%Named executive officers earned annual bonuses under the 2025 Bonus Plan at 90% of target payout levels.
  • $545KHelen Collins and Ben Hohl received base salary increases in January 2026 to $545,000 and $530,000 respectively.

About this page

Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.